NCT02586675 2022-01-21
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
H. Lee Moffitt Cancer Center and Research Institute
Icahn School of Medicine at Mount Sinai
Eli Lilly and Company
AstraZeneca